Log in

OTCMKTS:ENOBEnochian Biosciences Stock Price, Forecast & News

$4.12
+0.27 (+7.01 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.92
Now: $4.12
$4.15
50-Day Range
$3.06
MA: $3.73
$4.25
52-Week Range
$1.95
Now: $4.12
$7.08
Volume46,462 shs
Average Volume52,540 shs
Market Capitalization$191.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ENOB
CUSIPN/A
CIKN/A
Phone510-203-4857

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$191.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for ENOB and its competitors with MarketBeat's FREE daily newsletter.

Enochian Biosciences (OTCMKTS:ENOB) Frequently Asked Questions

How has Enochian Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Enochian Biosciences' stock was trading at $2.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENOB stock has increased by 83.1% and is now trading at $4.12. View which stocks have been most impacted by Coronavirus.

How were Enochian Biosciences' earnings last quarter?

Enochian Biosciences Inc (OTCMKTS:ENOB) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.03) earnings per share for the quarter. View Enochian Biosciences' earnings history.

Has Enochian Biosciences been receiving favorable news coverage?

News headlines about ENOB stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enochian Biosciences earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutEnochian Biosciences.

Who are some of Enochian Biosciences' key competitors?

What other stocks do shareholders of Enochian Biosciences own?

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the OTCMKTS under the ticker symbol "ENOB."

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.41%), Geode Capital Management LLC (0.55%), State Street Corp (0.27%), Bank of New York Mellon Corp (0.08%), Wells Fargo & Company MN (0.07%) and JPMorgan Chase & Co. (0.05%). Company insiders that own Enochian Biosciences stock include Henrik Gronfeldt-Sorensen and Rene Sindlev. View institutional ownership trends for Enochian Biosciences.

Which major investors are selling Enochian Biosciences stock?

ENOB stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Enochian Biosciences.

Which major investors are buying Enochian Biosciences stock?

ENOB stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, BlackRock Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN, Parametric Portfolio Associates LLC, and JPMorgan Chase & Co.. Company insiders that have bought Enochian Biosciences stock in the last two years include Henrik Gronfeldt-Sorensen, and Rene Sindlev. View insider buying and selling activity for Enochian Biosciences.

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $4.12.

How big of a company is Enochian Biosciences?

Enochian Biosciences has a market capitalization of $191.57 million.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is www.enochianbio.com.

How can I contact Enochian Biosciences?

The company can be reached via phone at 510-203-4857.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.